United Therapeutics (UTHR) Downgraded by ValuEngine

ValuEngine lowered shares of United Therapeutics (NASDAQ:UTHR) from a strong-buy rating to a buy rating in a report published on Friday morning.

UTHR has been the subject of several other reports. Zacks Investment Research raised United Therapeutics from a strong sell rating to a hold rating in a research report on Monday, October 9th. HC Wainwright reissued a hold rating and issued a $95.00 price target on shares of United Therapeutics in a research report on Thursday, October 26th. Cowen reissued a hold rating and issued a $129.00 price target on shares of United Therapeutics in a research report on Friday, October 27th. Oppenheimer boosted their price target on United Therapeutics to $180.00 and gave the stock an outperform rating in a research report on Friday, January 5th. Finally, Credit Suisse Group reissued an underperform rating and issued a $118.00 price target on shares of United Therapeutics in a research report on Thursday, January 18th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. United Therapeutics has a consensus rating of Hold and a consensus target price of $140.27.

United Therapeutics (UTHR) opened at $133.31 on Friday. The company has a market capitalization of $5,760.00, a price-to-earnings ratio of 11.76 and a beta of 1.26. United Therapeutics has a 1 year low of $112.01 and a 1 year high of $169.89.

In related news, CEO Martine A. Rothblatt sold 1,253 shares of the business’s stock in a transaction on Friday, November 24th. The stock was sold at an average price of $124.07, for a total transaction of $155,459.71. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 7,061 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $121.12, for a total value of $855,228.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,396 shares of company stock worth $1,402,028. 7.80% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of UTHR. Alliancebernstein L.P. grew its stake in United Therapeutics by 4.0% during the 2nd quarter. Alliancebernstein L.P. now owns 30,767 shares of the biotechnology company’s stock valued at $3,991,000 after purchasing an additional 1,192 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in United Therapeutics by 8.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,272 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 180 shares during the last quarter. M&T Bank Corp grew its stake in United Therapeutics by 8.8% during the 2nd quarter. M&T Bank Corp now owns 2,217 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 179 shares during the last quarter. Voya Investment Management LLC grew its stake in United Therapeutics by 31.0% during the 2nd quarter. Voya Investment Management LLC now owns 59,750 shares of the biotechnology company’s stock valued at $7,751,000 after purchasing an additional 14,136 shares during the last quarter. Finally, AHL Partners LLP grew its stake in United Therapeutics by 67.8% during the 2nd quarter. AHL Partners LLP now owns 34,786 shares of the biotechnology company’s stock valued at $4,513,000 after purchasing an additional 14,057 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics (UTHR) Downgraded by ValuEngine” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2018/02/05/united-therapeutics-uthr-downgraded-by-valuengine.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit